Evidence map›Paper›PMID 25383230›Full record

ArticleCase reports in immunology2012

Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjögren's Syndrome.

Maria Giovanna Danieli, Lucia Pettinari, Ramona Morariu, Fernando Monteforte, Francesco Logullo

Open access · goldAbstract read
In one paragraph

Article in Case reports in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Mycophenolate for the Treatment of Primary Sjögren's Syndrome.Journal of translational internal medicine · 2020
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maria Giovanna DanieliClinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche & Ospedali Riuniti, Via Tronto 10, 60126 Ancona, Italy.
Lucia PettinariU.O. di Medicina-LPA, Presidio di Loreto, 66025 Loreto, Italy.
Ramona MorariuClinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche & Ospedali Riuniti, Via Tronto 10, 60126 Ancona, Italy.
Fernando MonteforteU.O. di Radiodiagnostica, Ospedale di Casarano, 73042 Lecce, Italy.
Francesco LogulloClinica Neurologica, Dipartimento di Medicina Sperimentale e Clinica, Polo Didattico Scientifico, Università Politecnica delle Marche & Azienda Ospedali Riuniti, Via Tronto 10, 60126 Ancona, Italy.
Marche Polytechnic University · ITOspedale Santa Maria di Loreto Nuovo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sensory neuronopathy is described in association with the Sjögren's syndrome (SS). We studied a 55-year-old woman with a 4-year history of progressive asymmetric numbness, distal tingling, and burning sensation in upper and lower limbs. In a few months, she developed ataxia with increased hypoanaesthesia. Electrodiagnostic tests revealed undetectable distal and proximal sensory nerve action potential in upper and lower limbs. Cervical spine magnetic resonance showed a signal hyperintensity of posterior columns. Previous treatment with high-dose glucocorticoids and azathioprine was ineffective. A combined treatment with intravenous immunoglobulin and mycophenolate mofetil was followed by a progressive and persistent improvement. This case documented the efficacy and the safety of the coadministration of intravenous immunoglobulin and mycophenolate mofetil in sensory neuronopathy associated with SS refractory to conventional immunosuppressive therapy.

Identifiers

PMID25383230
PMCPMC4207592
OpenAlexW2070899556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.